Affiliated with a Castle Connolly Top Hospital
Who is Dr. Greenberg, Hematologist in Stanford, CA?
Dr. Peter Greenberg, MD is a Hematologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified by the American Board of Internal Medicine. Dr. Greenberg completed his residency at Barnes Hospital. Dr. Greenberg is fluent in English and Spanish, and is currently seeing new patients. Dr. Greenberg’s practice accepts Kaiser Permanente, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Greenberg’s office at (650) 723-4000.
Where did Dr. Greenberg go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine CA | Stanford University School of Medicine,Stanford, Ca, United States
Residency: Barnes Hospital | Barnes-Jewish Hospital | Stanford University Medical Center
Is Dr. Greenberg board certified in Hematologist?
Yes, Dr. Peter Greenberg, MD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 1976, American Board of Internal Medicine since 1970
What languages does Dr. Greenberg speak?
Dr. Greenberg and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does Dr. Greenberg treat?
As a Hematologist, Dr. Greenberg diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Greenberg. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Myelodysplastic Syndrome
- 5q Minus Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes Treatment (PDQ®)
- Myelodysplastic Syndromes Treatment (PDQ)
- 5q minus syndrome
- MDS
- Preleukemia
- Bone marrow failure disorder
- Bone Marrow Failure Syndrome
- MDS with isolated del(5q)
- Chromosome 5q deletion syndrome
- Myelodysplastic syndrome, 5q deletion
ICD-10 Codes:
- D469: Myelodysplastic syndrome, unspecified
- D46Z: Other myelodysplastic syndromes
- C946: Myelodysplastic disease, not elsewhere classified
- D46C: Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
- D4620: Refractory anemia with excess of blasts, unspecified
Also known as:
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia in Remission
- Chronic Myeloid Leukemia
- Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)
- CMML
- Myelomonocytic Leukemia
- AML Leukemia
- Acute Myeloblastic Leukemia
- Acute Myelogenous Leukemia
- AML Leukemia in Remission
- Acute Myeloblastic Leukemia in Remission
- Acute Myelogenous Leukemia in Remission
ICD-10 Codes:
- C9310: Chronic myelomonocytic leukemia not having achieved remission
- C9200: Acute myeloblastic leukemia, not having achieved remission
- C9201: Acute myeloblastic leukemia, in remission
Also known as:
- Aplastic Anemia
- Diamond-Blackfan Anemia
- Anemia
- Diamond-Blackfan anemia
- Bone Marrow Failure Anemia
- Marrow Aplasia
- DBA
- Congenital pure red cell aplasia
- Inherited red cell aplasia
ICD-10 Codes:
- D619: Aplastic anemia, unspecified
- D6101: Constitutional (pure) red blood cell aplasia
Also known as:
- Anemia
- Low Red Blood Cell Count
- Low Hemoglobin
- Iron deficiency
ICD-10 Codes:
- D649: Anemia, unspecified
Also known as:
- Chronic Kidney Disease, Stage 3a
- Chronic Kidney Disease
- Chronic Kidney Disease (CKD)
- CKD Stage 3a
- Moderate Chronic Kidney Disease
ICD-10 Codes:
- N1831: Chronic kidney disease, stage 3a
Also known as:
- Blood and Bone Marrow Disorder
- Blood Disorder
- Bone Marrow Disease
- Hematologic Conditions
- Diseases of Blood-Forming Organs
ICD-10 Codes:
- D759: Disease of blood and blood-forming organs, unspecified
Also known as:
- Other Types of Pancytopenia
- Blood Disorder
- Rare pancytopenia
- Uncommon low blood counts
- Bone marrow failure
ICD-10 Codes:
- D61818: Other pancytopenia
Also known as:
- Other Primary Thrombocytopenia
- Platelet Disorder
- Other low platelet count
- Rare platelet disorder
- Idiopathic low platelets
ICD-10 Codes:
- D6949: Other primary thrombocytopenia
Which procedures does Dr. Greenberg perform as a Hematologist?
As a Hematologist, procedures performed by a Dr. Peter Greenberg may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Greenberg's office.
Does Dr. Greenberg accept my insurance?
Dr. Greenberg accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Greenberg accept in Stanford, CA?
Dr. Greenberg in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Alignment Health Plan
All Other Third Party
AllCare Health Plan
Blue Shield of California
CVS Health (formerly Aetna)
Elevance Health Inc. (formerly Anthem)
Express Scripts
Medicare
Sutter Health
UnitedHealthcare
View All Insurances
Where is Dr. Greenberg's office located?
Recognitions
Awards
International Prize for outstanding research in myelodysplastic syndro
Publications
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem
JOURL OF CLINICAL ONCOLOGY, 2013
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
JOURL OF CLINICAL ONCOLOGY, 2013
The multifaceted ture of myelodysplastic syndromes: clinical, molecular
Jourl of the tiol Comprehensive Cancer Network : JNCCN, 2013
Reduced rR expression and increased rD promoter methylation in CD34
BLOOD, 2012
Revised Intertiol Prognostic Scoring System for Myelodysplastic Syndromes
BLOOD, 2012
Molecular and genetic features of myelodysplastic syndromes
INTERTIOL JOURL OF LABORATORY HEMATOLOGY, 2012
Persol Omics Profiling Reveals Dymic Molecular and Medical Phenotypes
CELL, 2012
Myelodysplastic Syndromes: Dissecting the Heterogeneity
JOURL OF CLINICAL ONCOLOGY, 2011
Myelodysplastic Syndromes
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
Current therapeutic approaches for patients with myelodysplastic syndromes
BRITISH JOURL OF HAEMATOLOGY, 2010
A phase II intra-patient dose
AMERICAN JOURL OF HEMATOLOGY, 2009
NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
J t Comp Cancer Network, 2009
Myelodysplastic syndromes.
Jourl of the tiol Comprehensive Cancer Network, 2008
The costs of drugs used to treat myelodyspl
Jourl of the tiol Comprehensive Cancer Network, 2008
Intertiol MDS Risk Alysis Workshop (IMRAW)
Am J Hematology
Relative response of patients with myelodysplastic syndromes
Eur J Haematol, 2008
Phase II Study of Lelidomide in Transfusion-Dependent
Blood, 2008
Myelodysplastic Syndromes
Clinical Leukemia, 2007
Hematologic and cytogenetic response to lelidomide in myelodysplastic syndrome with chromosome 5q
New Eng J Med, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology.
Jourl of the tiol Comprehensive Cancer Network, 2006
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Jourl of the tiol Comprehensive Cancer Network, 2006
Clinical application and proposal for modification of the Intertiol Working Group
Blood, 2006
Magement of patients with higher risk myelodysplastic syndromes
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005
Mitoxantrone, etoposide
JOURL OF CLINICAL ONCOLOGY, 2004
A Decision Alysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes
Blood, 2004
Novel biospecific agents for the treatment of myelodysplastic syndromes.
J t Comprehensive Cancer Network, 2003
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
ANLS OF THE RHEUMATIC DISEASES, 2001
Implications of pathogenetic and prognostic features for magement of myelodysplastic syndromes
LANCET, 2001
Apoptosis and its role in the myelodysplastic syndromes
LEUKEMIA RESEARCH, 1998
Intertiol scoring system for evaluating prognosis in myelodysplastic syndromes
BLOOD, 1997
Maintence treatment of the anemia of myelodyspl
BLOOD, 1996
Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
SEMIRS IN HEMATOLOGY, 1996
Maintence treatment of the anemia of myelodysplastic syndromes with recombint human G
Blood, 1996
TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINT HUMAN GRANULOCYTE-COLONY
BLOOD, 1993
INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
SEMIRS IN ONCOLOGY, 1992
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
SEMIRS IN ONCOLOGY, 1992
FUNCTIOL INTERACTIONS BETWEEN COLONY
CANCER RESEARCH, 1990
EFFECTS OF CSFS IN PRELEUKEMIA
Greenberg, P. L., Negrin, R., gler, A., 1990
MAINTENCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINT HUMAN GRANULOCYTE
BLOOD, 1990
BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND TURAL
INTERTIOL JOURL OF CELL CLONING, 1990
EFFECTS OF RECOMBINT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE
LEUKEMIA, 1990
EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINT HUMAN GRANULOCYTE COLONY
Greenberg, P., Negrin, R., gler, A., Vincent, M., Donlon, T., 1990
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
ANLS OF INTERL MEDICINE, 1989
SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINT INTERLEUKIN
BLOOD, 1988
RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN
JOURL OF CELLULAR PHYSIOLOGY, 1987
BIOLOGIC TURE OF THE MYELODYSPLASTIC SYNDROMES
ACTA HAEMATOLOGICA, 1987
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem
JOURNAL OF CLINICAL ONCOLOGY, 2013
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
JOURNAL OF CLINICAL ONCOLOGY, 2013
Specific plasma autoantibody reactivity in myelodysplastic syndromes
Scientific Reports, 2013
The multifaceted nature of myelodysplastic syndromes: clinical, molecular
Journal of the National Comprehensive Cancer Network : JNCCN, 2013
Reduced rRNA expression and increased rDNA promoter methylation in CD34
BLOOD, 2012
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
BLOOD, 2012
Molecular and genetic features of myelodysplastic syndromes
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012
Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
CELL, 2012
Distinctive contact between CD34+ hematopoietic progenitors
Lab Investigation, 2012
Treatment of higher risk myelodyspl
LEUKEMIA RESEARCH, 2012
Myelodysplastic Syndromes: Dissecting the Heterogeneity
JOURNAL OF CLINICAL ONCOLOGY, 2011
Myelodysplastic Syndromes
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
Prospective assessment of effects on iron
LEUKEMIA RESEARCH, 2010
Current therapeutic approaches for patients with myelodysplastic syndromes
BRITISH JOURNAL OF HAEMATOLOGY, 2010
Relationship of differential gene expression profiles in CD34
BLOOD, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte
BLOOD, 2009
A phase II intra-patient dose
AMERICAN JOURNAL OF HEMATOLOGY, 2009
NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
J Nat Comp Cancer Network, 2009
Myelodysplastic syndromes.
Journal of the National Comprehensive Cancer Network, 2008
The costs of drugs used to treat myelodyspl
Journal of the National Comprehensive Cancer Network, 2008
International MDS Risk Analysis Workshop (IMRAW)
Am J Hematology
Predictive factors of response
Blood, 2008
Factors affecting response
J Clin Oncol, 2008
Relative response of patients with myelodysplastic syndromes
Eur J Haematol, 2008
Phase II Study of Lenalidomide in Transfusion-Dependent
Blood, 2008
Myelodysplastic Syndromes
Clinical Leukemia, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes
Leukemia Research, 2007
Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q
New Eng J Med, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network, 2006
A phase II study of the farnesyltransferase inhibitor tipifarnib
Blood, 2006
Myelodysplastic Syndromes: Clinical and Biological Advances
Cambridge University Press, Cambridge, England
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Journal of the National Comprehensive Cancer Network, 2006
Clinical application and proposal for modification of the International Working Group
Blood, 2006
Management of patients with higher risk myelodysplastic syndromes
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005
Mitoxantrone, etoposide
JOURNAL OF CLINICAL ONCOLOGY, 2004
A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes
Blood, 2004
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome
LEUKEMIA RESEARCH, 2003
Novel biospecific agents for the treatment of myelodysplastic syndromes.
J Nat Comprehensive Cancer Network, 2003
Myelodysplastic syndromes.
Hematology / the Education Program of the American Society of Hematolo, 2002
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
ANNALS OF THE RHEUMATIC DISEASES, 2001
Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes
LANCET, 2001
The Myelodysplastic Syndromes , .
Hematology: Basic Principles and Practice. 3rd Ed., Hoffman R, Benz E,, 2000
Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
Forum (Genoa, Italy), 1999
Apoptosis and its role in the myelodysplastic syndromes
LEUKEMIA RESEARCH, 1998
Bcl-2 expression by myeloid precursors in myelodysplastic syndromes
LEUKEMIA RESEARCH, 1998
Risk factors and their relationship to prognosis in myelodysplastic syndromes
LEUKEMIA RESEARCH, 1998
NCCN Practice Guidelines for Myelodysplastic Syndromes
Oncology, 1998
International scoring system for evaluating prognosis in myelodysplastic syndromes
BLOOD, 1997
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
BLOOD, 1996
GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation
BONE MARROW TRANSPLANTATION, 1996
Maintenance treatment of the anemia of myelodyspl
BLOOD, 1996
Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
SEMINARS IN HEMATOLOGY, 1996
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G
Blood, 1996
ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT
EXPERIMENTAL HEMATOLOGY, 1995
MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF
EXPERIMENTAL HEMATOLOGY, 1995
EFFECTS OF GRANULOCYTE-COLONY
LEUKEMIA, 1995
TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY
BLOOD, 1993
T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW
BLOOD, 1992
INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
SEMINARS IN ONCOLOGY, 1992
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
SEMINARS IN ONCOLOGY, 1992
Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size
--
TREATMENT OF MYELODYSPLASTIC SYNDROMES
BLOOD REVIEWS, 1991
EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS
BLOOD CELLS, 1991
FUNCTIONAL INTERACTIONS BETWEEN COLONY
CANCER RESEARCH, 1990
IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC
BLOOD, 1990
EFFECTS OF CSFS IN PRELEUKEMIA
Greenberg, P. L., Negrin, R., Nagler, A., 1990
MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN
BLOOD, 1990
BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND
INTERNATIONAL JOURNAL OF CELL CLONING, 1990
EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE
LEUKEMIA, 1990
HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE
BLOOD, 1990
EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE
Greenberg, P., Negrin, R., Nagler, A., Vincent, M., Donlon, T., 1990
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY
ANNALS OF INTERNAL MEDICINE, 1989
SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN
BLOOD, 1988
RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN
JOURNAL OF CELLULAR PHYSIOLOGY, 1987
BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES
ACTA HAEMATOLOGICA, 1987
Granulopoiesis in acute myeloid leukemia and preleukemia
New Engl J Med, 1971
What is Dr. Greenberg's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Greenberg's National Provider Identifier (NPI) number is 1912033978.
What common questions do patients ask about Dr. Greenberg?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Greenberg
What is Dr. Peter Greenberg's specialty?
Dr. Greenberg is a Hematologist near Stanford, CA. An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma. Contact Dr. Greenberg to book an appointment today.
Is this Dr. Peter Greenberg affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Greenberg is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Hematologist?
Explore Hematologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Peter Greenberg accepting new patients in Stanford, CA?
Yes, Dr. Peter Greenberg is accepting new patients at this time.
Does Dr. Peter Greenberg offer online booking?
Please contact Dr. Greenberg's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Peter Greenberg?
Please contact Dr. Greenberg's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Peter Greenberg have?
Dr. Peter Greenberg is certified by the American Board of Internal Medicine.
Other Hematologist Near Stanford, CA
Hematologist
Accepting patientsHematologist
Accepting patientsMedical Oncologist
Accepting patients